CROs offering In Vivo PK / PD Studies with Antibody-Drug Conjugate (ADC)
18 published
18 published CROs match In Vivo PK / PD Studies and Antibody-Drug Conjugate (ADC).
Locations in this set include United States, China, France, Australia, India, and Japan.
Capabilities that show up most often in this set: Preclinical In Vivo Studies, Discovery Research, In Vitro Pharmacology, In Vivo Efficacy Models, and Preclinical In Vitro Studies.
Matching companies
Acres BiosciencesSan Diego CRO offering cell line engineering, high-throughput and functional assay development, and in vivo PK/PD and toxicity studies. Work spans oncology, fibrosis, and metabolic disease models, with T cell engager and ADC assay services.
Aliri BioanalysisBioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
AllucentAllucent is a full-service CRO specializing in clinical development solutions for small and mid-sized biotech companies.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
ChemDivChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Crown BiosciencePreclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
KCAS BioLeading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
Oncodesign ServicesContract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/in-vivo-pk-pd/antibody-drug-conjugate.md